FS Development Corp. II announced the pricing of its upsized $175 million IPO this evening and its shares are expected to begin trading on the Nasdaq under the symbol “FSII,” Wednesday, February 17.

The new company aims to combine with a biotechnology or life sciences business with a potentially market-leading product. FS II is led by President and CEO Jim Tananbaum, CFO Dennis Ryan and VP Michael Rome.

Total SPAC deal count for 2021 year-to-date is now 147 with $44.9 billion in gross proceeds raised. This offering is expected to close on Friday, February 19.

Jefferies LLC acting as the book-running manager for the offering. White & Case LLP is serving as Issuer’s Counsel with Skadden, Arps, Slate, Meagher & Flom LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.